All Stories

  1. The outcome of ulcerative colitis patients undergoing pouch surgery is determined by pre-surgical factors
  2. Magnetic resonance enterography or video capsule endoscopy – what do Crohn’s disease patients prefer?
  3. Impact of demographic and clinical parameters on video capsule transit time
  4. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis
  5. Tu1954 Capsule Endoscopy Findings and Fecal Calprotectin Levels Predict Clinical Relapse in Patients With Quiescent Small Bowel Crohn's Disease
  6. Clinical recurrence and re-resection rates after extensive vs. segmental colectomy in Crohn’s colitis: a retrospective cohort study
  7. Randomized clinical study: Partially hydrolyzed guar gum (PHGG) versus placebo in the treatment of patients with irritable bowel syndrome
  8. The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn’s Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study
  9. Cogan’s Syndrome in Patients With Inflammatory Bowel Disease – A Case Series
  10. Sa1177 Ulcerative Colitis Patients Undergoing Pouch Surgery Due to Non-Refractory Disease Have a Better Outcome Compared to Those Operated Due to Refractory Inflammation
  11. Tu1383 Serologic and Genetic Markers May Predict the Development of Chronic Pouchitis After Pouch Surgery in Ulcerative Colitis Patients
  12. Tu1324 Unfavorable Initial Thiopurine Response Does Not Reduce Anti-Drug Antibody Formation Compared to Thiopurine Responders in Crohn's Disease Patients Treated by Thiopurine & Infliximab Co-Therapy
  13. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents
  14. Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
  15. Prognosis of Primary Sclerosing Cholangitis in Israel is Independent of Coexisting Inflammatory Bowel Disease
  16. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease
  17. Gene expression alterations in ulcerative colitis patients after restorative proctocolectomy extend to the small bowel proximal to the pouch
  18. Mo1261 Thrombosis in Inflammatory Bowel Disease Patients Is Driven by Inflammation Rather Than by Thrombophilia
  19. Tu1928 Gene Expression Alterations Suggest That Ulcerative Colitis Patients After Restorative Proctocolectomy Have Ileal Disease
  20. Sa1258 The Clinical and Immunological Significance of Low Level of Infliximab in the Absence of Anti-Infliximab Antibodies in Patients With IBD
  21. Sa1250 Population Pharmacokinetic Evaluation of Adlimumab Reveals Patient Factors That Increase Adalimumab Clearance and Shorten Half-Life in Inflammatory Bowel Disease Patients
  22. Tu1929 MicroRNAs Expression in Ileal Inflammatory Bowel Disease Correlates With Disease Behavior
  23. Su1121 Anti-TNF and Anti-Drug Antibodies Levels Predict the Outcomes of Interventions After Loss of Response to Adalimumab and Infliximab
  24. P122 The clinical and immunological significance of low level of infliximab in the absence of anti-infliximab antibodies in patients with IBD
  25. The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies
  26. Gene Expression Profiles of Ileal Inflammatory Bowel Disease Correlate with Disease Phenotype and Advance Understanding of Its Immunopathogenesis
  27. Tu1145 Population Pharmacokinetic Evaluation of Infliximab Reveals Patient Factors That Increase Infliximab Clearance and Shorten Half-Life in Inflammatory Bowel Disease Patients
  28. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis
  29. Tu1267 The Questionable Value of Infliximab Trough Levels During Prolonged Maintenance Therapy
  30. Sa2032 Infliximab for Moderate to Severe Ulcerative Colitis: Short and Long-Term Effects and Predictors of Response
  31. Sa1223 The Incidence and Predictors of Lupus-Like Reactions in IBD Patients Treated With Anti-TNF Therapies
  32. Why do we Still Use 5-ASAs in Crohn's Disease?
  33. The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
  34. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile
  35. Assessing Response and Loss of Response to Biological Therapies in IBD
  36. W1322 The Practice of North-American Gastroenterologists in Treating IBD Patients With C.Difficile: Antibiotics Alone or Combined Antibiotics-Immunomodulators?
  37. Familial clustering of Crohnʼs disease in Israel: Prevalence and association with disease severity
  38. Role of colonoscopy in patients with persistent acute diverticulitis
  39. Patient Satisfaction with Endoscopy Measurement and Assessment
  40. The feasibility and risk of early colonoscopy in acute diverticulitis: a prospective controlled study
  41. Early Colonoscopy in Acute Diverticulitis-A Randomized Controlled Study
  42. Diverticulitis in the young patient-Is it different
  43. Autoimmune Aspects of Primary Pulmonary Hypertension